Research location
Pahrump
Nevada, United States
Advertisement
Research activity in Pahrump
Nevada, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 72 trials and 72 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Pahrump
72 linked trials · page 2 of 2A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes MellitusNCT01106651 · 2010-06-01 · 1 site observation
COMPLETED
12-week Efficacy of IndacaterolNCT01072448 · 2010-01-01 · 1 site observation
COMPLETED
Dapagliflozin DPPIV Inhibitor add-on StudyNCT00984867 · 2009-10-01 · 1 site observation
COMPLETED
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary SyndromeNCT00968708 · 2009-09-01 · 1 site observation
COMPLETED
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of PioglitazoneNCT00763815 · 2008-09-01 · 1 site observation
COMPLETED
A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.NCT00744926 · 2008-08-01 · 1 site observation
COMPLETED
A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. MetforminNCT00386100 · 2006-10-01 · 1 site observation
COMPLETED
DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant HypertensionNCT00353574 · 2006-09-01 · 1 site observation
TERMINATED
DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant HypertensionNCT00330369 · 2006-06-01 · 1 site observation
COMPLETED
Study In People With Type 2 DiabetesNCT00196989 · 2005-09-01 · 1 site observation
COMPLETED
G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)NCT00255645 · 2005-09-01 · 1 site observation
TERMINATED
A Study of DPP-IV Inhibitor in Patients With Type 2 DiabetesNCT00111670 · 2005-06-01 · 1 site observation
COMPLETED
A Phase II Study to Evaluate the Effects of Oral ONO-5129 in Type 2 Diabetes MellitusNCT00212641 · 2005-06-01 · 1 site observation
COMPLETED
A New Oral Treatment For Type II Diabetes MellitusNCT00111800 · 2005-04-28 · 1 site observation
COMPLETED
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPDNCT00206167 · 2005-04-01 · 1 site observation
COMPLETED
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD PatientsNCT00206154 · 2005-04-01 · 1 site observation
COMPLETED
GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes MellitusNCT00226330 · 2005-03-01 · 1 site observation
TERMINATED
GALLEX 1 - Long Term Extension Study in Patients With Type 2 DiabetesNCT00252876 · 2005-03-01 · 1 site observation
TERMINATED
GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 DiabetesNCT00229710 · 2005-02-01 · 1 site observation
TERMINATED
GALLANT 9 Tesaglitazar vs. Placebo in Combination With InsulinNCT00242372 · 2004-08-01 · 1 site observation
TERMINATED
Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On InsulinNCT00329225 · 2002-09-01 · 1 site observation
COMPLETED
GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 DiabetesNCT00280865 · 2002-04-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.